株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

神経変性疾患の世界市場 (2015〜2019年)

Global Neurodegenerative Diseases Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 329645
出版日 ページ情報 英文 168 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
神経変性疾患の世界市場 (2015〜2019年) Global Neurodegenerative Diseases Market 2015-2019
出版日: 2015年05月06日 ページ情報: 英文 168 Pages
概要

神経変性疾患とは、脳内部のニューロンに関連する症状のことで、人体のバランスや動き、発生、呼吸・心拍機能に悪影響を及ぼします。その原因についてはまだ何も分かっておらず、また治療法も確立されていません。神経細胞を段階的に変質させ、人体を大きく消耗させ、最終的には死に至ります。また、運動失調や痴呆症などを引き起こし、患者のメンタルヘルスにも大きく影響してきます。神経変性疾患の主な種類として、アルツハイマー病やパーキンソン病、ハンチントン病、多発性硬化症、ALS (筋萎縮性側索硬化症)、てんかんなどが挙げられます。このうち、アルツハイマー病やパーキンソン病は比較的に発症件数の多い疾患ですが、ハンチントン病やALSは難病に区分されます。世界の神経変性疾患市場は2014〜2019年にかけて、4.77%の年平均成長率 (CAGR) で成長する見通しです。

当レポートでは、全世界の神経変性疾患の関連市場について分析し、疾患の概要や主な治療薬、市場規模の動向 (今後5年間の予測値)、主な疾患別・分子の種類別・投与経路別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております。

第1章 エグゼクティブサマリー

第2章 略語集

第3章 分析範囲

  • 市場概要
  • 主な製品

第4章 製品プロファイル (計18品目)

第5章 市場分析の手法

  • 市場分析のプロセス
  • 分析手法

第6章 イントロダクション

第7章 市場環境

  • 市場概況
  • 市場規模とその予測
  • ファイブフォース分析

第8章 神経変性疾患の世界市場:疾患の種類別の内訳

第9章 多発性硬化症の世界市場

  • 多発性硬化症の概要
    • 疾患概要
    • 症状
    • 病因
    • 疫学
    • 経済的負担
  • 市場概要
  • 市場規模とその予測
  • 米国市場:市場規模と予測

第10章 アルツハイマー病の世界市場

第11章 てんかんの世界市場

第12章 パーキンソン病の世界市場

第13章 ハンチントン病の世界市場

第14章 筋萎縮性側索硬化症 (ALS) の世界市場

第15章 神経変性疾患の世界市場の内訳:分子の種類別

  • 生物製剤
  • 小分子

第16章 神経変性疾患の世界市場の内訳:投与経路別

  • 経口
  • 非経口
  • 局所

第17章 地域区分

第18章 購入基準

第19章 市場の成長促進要因

第20章 促進要因とその影響力

第21章 市場の課題

第22章 促進要因・課題の影響力

第23章 市場の傾向

第24章 市場動向とその影響

第25章 ベンダー環境

  • 競争シナリオ
    • 近年の主な動向
    • 企業合併・買収 (M&A)
  • 市場シェア分析
    • 主な医薬品の競合的評価
  • その他の著名な/将来性のあるベンダー

第26章 主要ベンダーの分析

  • Biogen Idec
    • 主要データ
    • 事業概要
    • 部門別の市場収益額
    • 地域別の市場収益額
    • 事業戦略
    • 最近の発展動向
    • SWOT分析
  • Merck Serono
  • Novartis
  • Pfizer
  • Teva Pharmaceutical
  • UCB

第27章 関連レポート

図表一覧

図表
  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Neurodegenerative Diseases Market 2014-2019 ($ million)
  • Exhibit 3: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease
  • Exhibit 4: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2014
  • Exhibit 5: Segmentation of Global Neurodegenerative Diseases Market by Type of Disease 2019
  • Exhibit 6: Etiology of Multiple Sclerosis
  • Exhibit 7: Global Multiple Sclerosis Market 2014-2019 ($ million)
  • Exhibit 8: Multiple Sclerosis Market in US 2014-2019 ($ million)
  • Exhibit 9: Prevalence of Dementia by Geography 2013, 2030, and 2050 (million)
  • Exhibit 10: Prevalence of Dementia by Geography 2013-2018 (millions)
  • Exhibit 11: Types of Dementia and Associated Symptoms
  • Exhibit 12: Types of Dementia by Prevalence 2013
  • Exhibit 13: Segmentation of Economic Burden of Alzheimer's Disease and Other Dementias by Geography 2013
  • Exhibit 14: Average Cost of Care for Americans Aged 65 and Above with Alzheimer's Disease and Other Dementias 2013
  • Exhibit 15: Distribution of Alzheimer's Caregivers by Age 2013
  • Exhibit 16: Projected Prevalence of Dependence 2010 and 2030
  • Exhibit 17: Global Alzheimer's Disease Market 2014-2019 ($ million)
  • Exhibit 18: Global Epilepsy Market 2014-2019 ($ million)
  • Exhibit 19: Epilepsy Market in US 2014-2019 ($ million)
  • Exhibit 20: Epilepsy Market in Europe 2014-2019 ($ million)
  • Exhibit 21: Epilepsy Market in Japan 2014-2019 ($ million)
  • Exhibit 22: Global Parkinson's Disease Market 2014-2019 ($ million)
  • Exhibit 23: Segmentation of Global Parkinson's Disease Market by Country 2014
  • Exhibit 24: Snapshot of Disease
  • Exhibit 25: Prevalence of Huntington's Disease by Geography 2013
  • Exhibit 26: Huntington's Disease: Pipeline Portfolio
  • Exhibit 27: Global Huntington's Disease Market 2014-2019 ($ million)
  • Exhibit 28: Snapshot of Disease
  • Exhibit 29: Amyotrophic Lateral Sclerosis: Pipeline Portfolio
  • Exhibit 30: Global Amyotrophic Lateral Sclerosis Market 2014-2019 ($ million)
  • Exhibit 31: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule
  • Exhibit 32: Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule 2014
  • Exhibit 33: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration
  • Exhibit 34: Segmentation of Global Neurodegenerative Diseases Market by Route of Administration 2014
  • Exhibit 35: Segmentation of Global Neurodegenerative Diseases Market by Geography 2014
  • Exhibit 36: Global Neurodegenerative Diseases Market Share Analysis 2014
  • Exhibit 37: Major Drugs for Neurodegenerative Diseases by Revenue 2014 ($ million)
  • Exhibit 38: YoY Revenue of Major Drugs for Neurodegenerative Diseases 2011-2014 ($ million)
  • Exhibit 39: Revenue Share of Major Drugs for Neurodegenerative Diseases 2011-2014
  • Exhibit 40: Biogen Idec: Global Revenue of Products 2011-2014 ($ million)
  • Exhibit 41: Biogen Idec: YoY Global Revenue of Avonex 2011-2014 ($ million)
  • Exhibit 42: Biogen Idec: Revenue of Avonex in US 2011-2014 ($ million)
  • Exhibit 43: Biogen Idec: Revenue of Avonex in ROW 2011-2014 ($ million)
  • Exhibit 44: Biogen Idec: YoY Global Revenue of Tysabri 2011-2014 ($ million)
  • Exhibit 45: Biogen Idec: Revenue of Tysabri in US 2011-2014 ($ million)
  • Exhibit 46: Biogen Idec: Revenue of Tysabri in ROW 2011-2014 ($ million)
  • Exhibit 47: Biogen Idec: YoY Global Revenue of Fampyra 2011-2014 ($ million)
  • Exhibit 48: Biogen Idec: Revenue of Plegridy in US and ROW 2014 ($ million)
  • Exhibit 49: Biogen Idec: Revenue of Tecfidera in US and ROW 2013 and 2014 ($ million)
  • Exhibit 50: Pfizer: YoY Global Revenue of Lyrica 2011-2014 ($ million)
  • Exhibit 51: Pfizer: YoY Global Revenue of Neurontin 2011-2013 ($ million)
  • Exhibit 52: Teva Pharmaceutical: YoY Global Revenue of Copaxone 2011-2014 ($ million)
  • Exhibit 53: Teva Pharmaceutical: Quarterly Revenue of Copaxone 2011-2014 ($ million)
  • Exhibit 54: Teva Pharmaceutical: YoY Global Revenue of Azilect 2011-2014 ($ million)
  • Exhibit 55: Teva Pharmaceutical: Quarterly Revenue of Azilect 2011-2014 ($ million)
  • Exhibit 56: Novartis: YoY Global Revenue of Gilenya 2011-2014 ($ million)
  • Exhibit 57: Novartis: Revenue of Gilenya in US and ROW 2011-2013 ($ million)
  • Exhibit 58: Novartis: YoY Global Revenue of Extavia 2011-2014 ($ million)
  • Exhibit 59: Novartis: YoY Global Revenue of Comtan/Stalevo 2011-2014 ($ million)
  • Exhibit 60: Novartis: Revenue of Comtan/Stalevo in US and ROW 2011-2013 ($ million)
  • Exhibit 61: Novartis: YoY Global Revenue of Exelon/Exelon Patch 2011-2014 ($ million)
  • Exhibit 62: Novartis: Revenue of Exelon/Exelon Patch in US and ROW 2011-2013 ($ million)
  • Exhibit 63: Merck Serono: YoY Global Revenue of Rebif 2011-2014 ($ million)
  • Exhibit 64: Merck Serono: Revenue of Rebif in North America 2011-2014 ($ million)
  • Exhibit 65: Merck Serono: Revenue of Rebif in Europe 2011-2014 ($ million)
  • Exhibit 66: Merck Serono: Revenue Share of Rebif by Region 2012-2014
  • Exhibit 67: UCB: YoY Global Revenue of Vimpat 2011-2014 ($ million)
  • Exhibit 68: UCB: YoY Revenue of Vimpat in Europe 2011-2014 ($ million)
  • Exhibit 69: UCB: YoY Revenue of Vimpat in North America 2011-2014 ($ million)
  • Exhibit 70: UCB: YoY Global Revenue of Keppra/Keppra XR 2011-2014 ($ million)
  • Exhibit 71: UCB: YoY Revenue of Keppra/Keppra XR in Europe 2011-2014 ($ million)
  • Exhibit 72: UCB: YoY Revenue of Keppra/Keppra XR in North America 2011-2014 ($ million)
  • Exhibit 73: UCB: YoY Global Revenue of Neupro 2011-2014 ($ million)
  • Exhibit 74: UCB: YoY Revenue of Neupro in Europe 2011-2014 ($ million)
  • Exhibit 75: UCB: YoY Revenue of Neupro in North America 2011-2014 ($ million)
  • Exhibit 76: Biogen Idec: Business Segmentation by Revenue 2013
  • Exhibit 77: Biogen Idec: Geographical Segmentation by Revenue 2013
  • Exhibit 78: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 79: Novartis AG: Business Segmentation
  • Exhibit 80: Novartis AG: Revenue by Business Segmentation 2013
  • Exhibit 81: Novartis AG: Revenue by Business Segmentation 2012 and 2013 ($ million)
  • Exhibit 82: Novartis AG: Revenue by Geographical Segmentation 2013
  • Exhibit 83: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 84: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 85: Pfizer: Geographical Segmentation by Revenue 2013
  • Exhibit 86: Teva Pharmaceutical Industries: Business Segmentation
  • Exhibit 87: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2013
  • Exhibit 88: Teva Pharmaceutical Industries: Business Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 89: Teva Pharmaceutical Industries: Sales by Geography 2013
  • Exhibit 90: UCB: Product Segmentation by Revenue 2013
  • Exhibit 91: UCB: Product Segmentation by Revenue 2012 and 2013 ($ million)
  • Exhibit 92: UCB: Geographical Segmentation by Revenue 2013
目次
Product Code: IRTNTR5793

About neurodegenerative diseases

According to the EU JPND, neurodegenerative diseases refer to conditions that involve the neurons in the brain. These conditions can affect balance, movement, speech, and respiratory and cardiac functions. They can be inherited or be of unknown etiology. Neurodegenerative diseases are incurable and are severely debilitating. They result in progressive degeneration of nerve cells, causing them to die eventually. These diseases cause ataxia and dementia in people, which can have a serious impact on the mental health of patients. Some examples of neurodegenerative diseases are Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, and epilepsy. Huntington's disease and amyotrophic lateral sclerosis are rare diseases, unlike Alzheimer's disease and Parkinson's disease which have a high degree of prevalence.

Technavio's analysts forecast the global neurodegenerative diseases market to grow at a CAGR of 4.77 percent over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global neurodegenerative diseases market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of neurodegenerative diseases. The market includes data from the sales of various drugs used in the treatment of:

  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the global neurodegenerative diseases market. The vendor landscape section includes a market share analysis of the major vendors along with the performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. In addition, late-stage pipeline molecules developed for the treatment of neurodegenerative diseases are discussed.

Technavio's report, Global Neurodegenerative Diseases Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC; it also covers the global neurodegenerative diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Biogen Idec
  • Merck Serono
  • Novartis
  • Pfizer
  • Teva Pharmaceutical Industries
  • UCB

Other prominent vendors

  • AB Science
  • Abbvie
  • Acorda Therapeutics
  • Actavis
  • Active Biotech
  • Adamas Pharmaceuticals
  • Akorn
  • Archer Pharmaceuticals
  • Astellas
  • Auspex Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Covis
  • Desitin Arzneimittel
  • Eisai
  • Eli Lilly
  • Endo International
  • F. Hoffmann-La Roche
  • FORUM Pharmaceuticals
  • GlaxoSmithKline
  • Glenmark
  • H. Lundbeck
  • Ipsen
  • Janssen Pharmaceuticals
  • Kyowa Hakko Kirin
  • Mitsubishi Tanabe
  • MorphoSys
  • Newron Pharmaceuticals
  • Omeros
  • Opexa
  • Orion
  • Otsuka Pharmaceutical
  • Oxford BioMedica
  • Palobiofarma
  • Prana Biotechnology
  • Raptor Pharmaceutical
  • Sanofi
  • Siena Biotech
  • SOM Biotech
  • STADA
  • Takeda Pharmaceutical
  • TauRx Pharmaceuticals
  • US WorldMeds
  • Valeant
  • Zinfandel Pharmaceuticals

Market driver

  • High unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Generic erosion
  • For a full, detailed list, view our report

Market trend

  • Reformulation of marketed drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Avonex/Rebif
    • 04.1.2. Plegridy
    • 04.1.3. Tecfidera
    • 04.1.4. Tysabri
    • 04.1.5. Comtan
    • 04.1.6. Stalevo
    • 04.1.7. Exelon/Exelon Patch
    • 04.1.8. Extavia
    • 04.1.9. Gilenya
    • 04.1.10. Cerebyx
    • 04.1.11. Dilantin-125
    • 04.1.12. Lyrica
    • 04.1.13. Neurontin
    • 04.1.14. Zarontin
    • 04.1.15. Azilect
    • 04.1.16. Copaxone
    • 04.1.17. Keppra/Keppra XR
    • 04.1.18. Neupro
    • 04.1.19. Vimpat

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Segmentation of Global Neurodegenerative Diseases Market by Type of Disease

09. Global Multiple Sclerosis Market

  • 09.1. Multiple Sclerosis: Overview
    • 09.1.1. About the Disease
    • 09.1.2. Symptoms
    • 09.1.3. Etiology
    • 09.1.4. Epidemiology
    • 09.1.5. Economic Burden
  • 09.2. Market Overview
  • 09.3. Market Size and Forecast
  • 09.4. Multiple Sclerosis Market in US
    • 09.4.1. Market Size and Forecast

10. Global Alzheimer's Disease Market

  • 10.1. Alzheimer's Disease: Overview
    • 10.1.1. About the Disease
    • 10.1.2. Dementia
    • 10.1.3. Epidemiology and Forecast
    • 10.1.4. Types of Dementia
    • 10.1.5. Global Burden
    • 10.1.6. Etiology
    • 10.1.7. Cost of Care
    • 10.1.8. Alzheimer's Disease and Caregiving
  • 10.2. Market Overview
  • 10.3. Market Size and Forecast

11. Global Epilepsy Market

  • 11.1. Epilepsy: Overview
    • 11.1.1. About the Disease
    • 11.1.2. Etiology
    • 11.1.3. Types of Epilepsy
    • 11.1.4. Symptoms
    • 11.1.5. Epidemiology
    • 11.1.6. Economic Burden
  • 11.2. Market Overview
  • 11.3. Market Size and Forecast
  • 11.4. Epilepsy Market in US
    • 11.4.1. Market Size and Forecast
  • 11.5. Epilepsy Market in Europe
    • 11.5.1. Market Size and Forecast
  • 11.6. Epilepsy Market in Japan
    • 11.6.1. Market Size and Forecast

12. Global Parkinson's Disease Market

  • 12.1. Parkinson's Disease: Overview
    • 12.1.1. About the Disease
    • 12.1.2. Symptoms
    • 12.1.3. Etiology
    • 12.1.4. Epidemiology
    • 12.1.5. Economic Burden
  • 12.2. Market Overview
  • 12.3. Market Size and Forecast

13. Global Huntington's Disease Market

  • 13.1. Huntington's Disease: Overview
    • 13.1.1. About the Disease
    • 13.1.2. Symptoms
    • 13.1.3. Etiology
    • 13.1.4. Prevalence of Huntington's Disease
    • 13.1.5. Pipeline Portfolio
    • 13.1.6. Economic Burden
  • 13.2. Market Overview
  • 13.3. Market Size and Forecast

14. Global Amyotrophic Lateral Sclerosis Market

  • 14.1. Amyotrophic Lateral Sclerosis: Overview
    • 14.1.1. About the Disease
    • 14.1.2. Types of Amyotrophic Lateral Sclerosis
    • 14.1.3. Etiology and Pathophysiology
    • 14.1.4. Symptoms
    • 14.1.5. Epidemiology
    • 14.1.6. Diagnosis
    • 14.1.7. Pipeline Portfolio
  • 14.2. Market Overview
  • 14.3. Market Size and Forecast

15. Segmentation of Global Neurodegenerative Diseases Market by Type of Molecule

  • 15.1. Biologics
  • 15.2. Small Molecules

16. Segmentation of Global Neurodegenerative Diseases Market by Route of Administration

  • 16.1. Oral
  • 16.2. Parenteral
  • 16.3. Topical

17. Geographical Segmentation

18. Buying Criteria

19. Market Growth Drivers

20. Drivers and their Impact

21. Market Challenges

22. Impact of Drivers and Challenges

23. Market Trends

24. Trends and their Impact

25. Vendor Landscape

  • 25.1. Competitive Scenario
    • 25.1.1. Key News
    • 25.1.2. Mergers and Acquisitions
  • 25.2. Market Share Analysis 2014
    • 25.2.1. Competitive Assessment of Major Drugs
    • 25.2.2. Biogen Idec
    • 25.2.3. Pfizer
    • 25.2.4. Teva Pharmaceutical
    • 25.2.5. Novartis
    • 25.2.6. Merck Serono
    • 25.2.7. UCB
  • 25.3. Other and Potential Future Prominent Vendors

26. Key Vendor Analysis

  • 26.1. Biogen Idec
    • 26.1.1. Key Facts
    • 26.1.2. Business Overview
    • 26.1.3. Business Segmentation by Revenue 2013
    • 26.1.4. Geographical Segmentation by Revenue 2013
    • 26.1.5. Business Strategy
    • 26.1.6. Key Developments
    • 26.1.7. SWOT Analysis
  • 26.2. Merck Serono
    • 26.2.1. Key Facts
    • 26.2.2. Business Overview
    • 26.2.3. Geographical Segmentation by Revenue 2013
    • 26.2.4. Business Strategy
    • 26.2.5. Recent Developments
    • 26.2.6. SWOT Analysis
  • 26.3. Novartis
    • 26.3.1. Key Facts
    • 26.3.2. Business Description
    • 26.3.3. Business Segmentation
    • 26.3.4. Revenue by Business Segmentation
    • 26.3.5. Revenue Comparison 2012 and 2013
    • 26.3.6. Sales by Geography
    • 26.3.7. Business Strategy
    • 26.3.8. Key Developments
    • 26.3.9. SWOT Analysis
  • 26.4. Pfizer
    • 26.4.1. Key Facts
    • 26.4.2. Business Overview
    • 26.4.3. Business Segmentation by Revenue 2013
    • 26.4.4. Business Segmentation by Revenue 2012 and 2013
    • 26.4.5. Geographical Segmentation by Revenue
    • 26.4.6. Business Strategy
    • 26.4.7. Key Developments
    • 26.4.8. SWOT Analysis
  • 26.5. Teva Pharmaceutical
    • 26.5.1. Key Facts
    • 26.5.2. Business Overview
    • 26.5.3. Business Segmentation
    • 26.5.4. Business Segmentation by Revenue 2013
    • 26.5.5. Business Segmentation by Revenue 2012 and 2013
    • 26.5.6. Sales by Geography
    • 26.5.7. Business Strategy
    • 26.5.8. Key Developments
    • 26.5.9. SWOT Analysis
  • 26.6. UCB
    • 26.6.1. Key Facts
    • 26.6.2. Business Overview
    • 26.6.3. Product Segmentation by Revenue 2013
    • 26.6.4. Product Segmentation by Revenue 2012 and 2013
    • 26.6.5. Geographical Segmentation by Revenue 2013
    • 26.6.6. Business Strategy
    • 26.6.7. Recent Developments
    • 26.6.8. SWOT Analysis

27. Other Reports in this Series

Back to Top